1. Generics Bulletin
  2. >>Business
  3. >>Deals

Hyloris And Hikma Ally On Maxigesic IV In US

Firms Strike Marketing Partnership For Intravenous Paracetamol/Ibuprofen

 
• By Dave Wallace

Hyloris has secured Hikma as its US marketing partner for Maxigesic IV. The deal gives Hyloris access to Hikma’s presence in complex, injectable hospital products while aligning with Hikma’s push into differentiated treatments.

US Flag Handshake Deal
Hyloris and Hikma have struck a US marketing deal for Maxigesic IV • Source: Alamy

Hyloris has announced a collaboration that will see Hikma act as the Belgian value added medicines specialist’s US licensee for its Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg intravenous analgesic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.